Completed PHASE3 INTERVENTIONAL 3-arm NCT00389207

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.

Sponsor: Boehringer Ingelheim

Conditions HIV Infections

Interventions atazanavir nevirapine bid nevirapine qd

Updated 6 times since 2017 Last updated: Dec 9, 2013 Started: Oct 31, 2006 Primary completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00389207, this PHASE3 trial focuses on HIV Infections and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 6 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Alcalá de Henares (Madrid), Spain , Badalona, Spain , Barcelona, Spain , Bergamo, Italy , Berlin, Germany , Bern, Switzerland , Birmingham, United Kingdom , Bochum, Germany , Bologna, Italy and 47 more locations